small molecule therapeutic for autism/obsessive compulsive disorder (Rugen Therapeutics/Allergan)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namesmall molecule therapeutic for autism/obsessive compulsive disorder (Rugen Therapeutics/Allergan)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsAutistic DisorderObsessive-Compulsive Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIrelandMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesRugen Therapeutics R & D (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRugen Therapeutics R & D (Shanghai) Co LtdAllergan Plc
Active IndicationsN/A
Inactive IndicationsAutistic DisorderObsessive-Compulsive Disorder

Other Information

ATC CodeN/A
Related LinksN/A